Coherus BioSciences (CHRS) Tops Q2 EPS by 14c, beats revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.33 -0.75%
Revenue Growth %: +37.8%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: +37.8%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.7 million versus the consensus estimate of $50.47 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print
- Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
